[go: up one dir, main page]

MX2016000344A - Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn. - Google Patents

Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn.

Info

Publication number
MX2016000344A
MX2016000344A MX2016000344A MX2016000344A MX2016000344A MX 2016000344 A MX2016000344 A MX 2016000344A MX 2016000344 A MX2016000344 A MX 2016000344A MX 2016000344 A MX2016000344 A MX 2016000344A MX 2016000344 A MX2016000344 A MX 2016000344A
Authority
MX
Mexico
Prior art keywords
immunoglobulin
conjugate
fragment
fcrn binding
binding strength
Prior art date
Application number
MX2016000344A
Other languages
English (en)
Other versions
MX376370B (es
Inventor
Se Chang Kwon
Sung Youb Jung
In Young Choi
Jong Soo Lee
Sung Hee Hong
Sang Youn Hwang
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2016000344A publication Critical patent/MX2016000344A/es
Publication of MX376370B publication Critical patent/MX376370B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un conjugado de polipéptido fisiológicamente activo y fragmento Fc de inmunoglobulina que comprende un polipéptido fisiológicamente activo unido a través de un enlazador no peptídico a un fragmento Fc de inmunoglobulina que tiene una región de unión a FcRn y mantiene la afinidad de unión intrínseca del fragmento Fc de inmunoglobulina, un método de preparación del conjugado, un método de mantenimiento de la afinidad de unión intrínseca del conjugado hacia FcRn y una composición que comprende el conjugado que mantiene la afinidad de unión intrínseca del fragmento Fc de inmunoglobulina hacia FcRn.
MX2016000344A 2013-07-12 2014-07-14 Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn. MX376370B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20130082509 2013-07-12
PCT/KR2014/006328 WO2015005747A1 (ko) 2013-07-12 2014-07-14 FcRn 결합력이 유지되는 면역글로불린 Fc 결합체

Publications (2)

Publication Number Publication Date
MX2016000344A true MX2016000344A (es) 2016-05-05
MX376370B MX376370B (es) 2025-03-07

Family

ID=52280325

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000344A MX376370B (es) 2013-07-12 2014-07-14 Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn.

Country Status (21)

Country Link
US (2) US20160152684A1 (es)
EP (1) EP3020732B1 (es)
JP (2) JP2016525099A (es)
KR (2) KR101872559B1 (es)
CN (2) CN105593243A (es)
AR (1) AR096890A1 (es)
AU (1) AU2014287879B2 (es)
CA (1) CA2917838C (es)
DK (1) DK3020732T3 (es)
EA (1) EA034297B1 (es)
ES (1) ES2799326T3 (es)
HU (1) HU231424B1 (es)
IL (1) IL243567B (es)
MX (1) MX376370B (es)
MY (1) MY180374A (es)
NO (1) NO20160182A1 (es)
PH (1) PH12016500111A1 (es)
PT (1) PT3020732T (es)
TW (1) TWI693236B (es)
UA (1) UA119644C2 (es)
WO (1) WO2015005747A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
MX387560B (es) * 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
WO2018117613A1 (ko) * 2016-12-19 2018-06-28 한미약품 주식회사 뇌 표적 지속성 단백질 결합체
KR102282240B1 (ko) 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
WO2021010531A1 (ko) * 2019-07-18 2021-01-21 한미약품 주식회사 단백질 결합체의 신규 제조 방법
KR102382593B1 (ko) * 2020-01-29 2022-04-05 고려대학교 산학협력단 pH-감응성 Fc 변이체

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CN1852732A (zh) * 2002-12-26 2006-10-25 山景医药公司 具有增强的生物学效用的干扰素－β的聚合物缀合物
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
RU2352583C2 (ru) * 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
KR100609434B1 (ko) 2004-12-30 2006-08-03 한국항공우주연구원 트랜스버살 필터
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
KR20080098216A (ko) * 2007-05-04 2008-11-07 한미약품 주식회사 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체
BRPI0811637B8 (pt) * 2007-05-30 2021-05-25 Genexine Inc proteínas de fusão da imunoglobulina
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
CN102112493B (zh) * 2008-07-23 2015-04-01 韩美科学株式会社 包含具有三个官能性末端的非肽基聚合物的多肽复合物
KR20150002894A (ko) * 2010-03-11 2015-01-07 리나트 뉴로사이언스 코프. ｐＨ 의존성 항원 결합을 갖는 항체
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101337797B1 (ko) * 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101333958B1 (ko) * 2010-10-20 2013-11-27 주식회사 한독 인간 인터루킨-1 수용체 길항제-하이브리드 Ｆｃ 융합단백질
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
DK3878859T5 (da) 2011-06-10 2024-06-10 Hanmi Science Co Ltd Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
SI2721062T1 (sl) * 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
CN103611163A (zh) * 2011-09-05 2014-03-05 韩美科学株式会社 一种包含干扰素α-缀合物的抗癌用药物组合物
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada

Also Published As

Publication number Publication date
JP6880278B2 (ja) 2021-06-02
PT3020732T (pt) 2020-06-25
EA034297B1 (ru) 2020-01-27
NO20160182A1 (en) 2016-03-02
CA2917838C (en) 2023-06-20
KR20180071241A (ko) 2018-06-27
TWI693236B (zh) 2020-05-11
ES2799326T3 (es) 2020-12-16
JP2016525099A (ja) 2016-08-22
JP2020125337A (ja) 2020-08-20
CA2917838A1 (en) 2015-01-15
AR096890A1 (es) 2016-02-03
EA201690114A1 (ru) 2016-07-29
EP3020732A4 (en) 2016-12-28
PH12016500111A1 (en) 2016-04-18
DK3020732T3 (da) 2020-06-15
CN105593243A (zh) 2016-05-18
EP3020732A1 (en) 2016-05-18
IL243567B (en) 2020-11-30
TW201546093A (zh) 2015-12-16
AU2014287879A1 (en) 2016-02-11
UA119644C2 (uk) 2019-07-25
IL243567A0 (en) 2016-03-31
WO2015005747A1 (ko) 2015-01-15
HU231424B1 (hu) 2023-08-28
US20160152684A1 (en) 2016-06-02
MY180374A (en) 2020-11-28
US20220380437A1 (en) 2022-12-01
HUP1600206A2 (hu) 2016-05-30
EP3020732B1 (en) 2020-03-18
KR101872559B1 (ko) 2018-06-28
NZ716275A (en) 2021-09-24
CN116082528A (zh) 2023-05-09
KR20150008011A (ko) 2015-01-21
MX376370B (es) 2025-03-07
AU2014287879B2 (en) 2020-01-02
KR102076718B1 (ko) 2020-02-12
HK1221957A1 (en) 2017-06-16

Similar Documents

Publication Publication Date Title
MX2016000344A (es) Un conjugado de fc de inmunoglobulina que mantiene la afinidad de union del fragmento fc de inmunoglobulina hacia fcrn.
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
MX374483B (es) Conjugados de anticuerpo-fynomer.
MX374811B (es) Anticuerpos anti-tau y métodos de uso.
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX2015006548A (es) Proteinas vinculantes que comprenden al menos dos dominios de repeticion contra her2.
IL243568B (en) Conjugation of a biologically active polypeptide monomer and an immunoglobulin fragment fc with a reduction in receptor elimination and a method for its preparation
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
MX2015010146A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
CU20160101A7 (es) Inmunoglobulina con fab en tándem
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201992456A3 (ru) Самостабилизирующиеся линкерные конъюгаты
MX2015011075A (es) Peptidos terapeuticos.
MX375441B (es) Fusocinas que implican citocinas con una afinidad de union al receptor considerablemente menor.
PH12016500123A1 (en) Therapeutic fusion protein
EA201690314A1 (ru) Анти-garp-белок и его применения
WO2014191113A8 (en) Novel antibodies
EA201591700A1 (ru) Гибридные белки апелина и их применение
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
EA201291065A1 (ru) Антитела против vla-4
WO2014140374A3 (en) Monovalent cd27 antibodies
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
CO7240413A2 (es) Composición farmacéutica que comprende fimasartan e hidroclorotiazida

Legal Events

Date Code Title Description
FG Grant or registration